pbo 508

Based on 60 patients per comparison treatment arm and the assumed mirikizumab and PBO endoscopic response rates of 35% and 15%, respectively, the test of the superiority versus PBO has 81% power when performed via a chi-squared test at a 2-sided 0.1 significance level. 508 miyako